6533b7dafe1ef96bd126ed06

RESEARCH PRODUCT

Pharmacokinetics of Droloxifene and Its Metabolites in Breast Cancer Patients

K. PollowH. J. Grill

subject

AdultOncologyDrugCancer Researchmedicine.medical_specialtymedia_common.quotation_subjectAdministration OralBiological AvailabilityAntineoplastic AgentsBreast NeoplasmsBioequivalenceBreast cancerPharmacokineticsInternal medicinemedicineHumansChromatography High Pressure LiquidAgedmedia_commonAged 80 and overbusiness.industryEstrogen AntagonistsCancerMiddle AgedAntiestrogenmedicine.diseaseTamoxifenOncologyTolerabilityDroloxifeneDrug EvaluationFemalebusinessHalf-Life

description

Pharmacokinetics and metabolism of droloxifene, a new antiestrogenic drug, have been investigated by single- and multiple-dose studies in postmenopausal patients with advanced breast cancer. Short terminal elimination half-life, low accumulation, and improved drug tolerability are the most striking features of this safe and effective new antiestrogen. Bioequivalence of film-coated tablet, tablet, and standard solution of droloxifene has been shown. The concentrations of droloxifene and its metabolites have been determined by a highly selective HPLC method.

https://doi.org/10.1097/00000421-199112002-00006